Phio Pharmaceuticals Corp. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Phio Pharmaceuticals Corp. on January 21, 2021, with the report date reflecting the earliest event reported. The filing details a material definitive agreement entered into on January 21, 2021, regarding a private placement of equity securities. The transaction closed on January 25, 2021.
Key Financial Metrics
The filing discloses the following financial details regarding the capital raise:
- Gross Proceeds: Approximately $14.0 million.
- Securities Issued:
- 4,420,863 shares of Common Stock at $3.07 per share.
- 140,065 Pre-funded Warrants at $3.069 per warrant (exercisable at $0.001).
- 3,420,696 Common Warrants (exercisable at $3.00 per share).
- Placement Agent Fees: 7.5% cash fee and 1.0% management fee of aggregate gross proceeds, plus up to $85,000 for non-accountable expenses.
- Placement Agent Warrants: Warrants to purchase 342,070 shares (7.5% of aggregate shares and pre-funded warrants) at an exercise price of $3.8375, expiring July 27, 2026.
The filing does not provide data on revenue, profit, cash flow, operating margins, existing debt, or liquidity positions outside of the proceeds from this specific transaction.
Material Changes
The primary material change is the increase in equity capital and the dilution of existing shareholders due to the issuance of new shares and warrants. The company agreed to file a registration statement for the resale of these securities no later than February 1, 2021, with an effectiveness deadline of April 21, 2021, subject to SEC review.
Outlook, Risks, and Contingencies
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosures regarding unregistered sales. The transaction relies on exemptions under Section 4(a)(2) and Rule 506 of the Securities Act of 1933. The Common Warrants are immediately exercisable and expire 5.5 years from issuance.
Investor Verification Checklist
- Verify the final net proceeds after deducting the 8.5% placement agent fees and offering expenses.
- Confirm the filing date and effectiveness status of the resale registration statement (S-1 or S-3) required by February 1, 2021.
- Review the full text of the Securities Purchase Agreement and Registration Rights Agreement filed as exhibits 10.1 and 10.2 for specific covenants or restrictions.
- Assess the immediate dilution impact of the 4.42 million shares and 3.42 million warrants issued.